Nasdaq

BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test

FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) ...
FierceBiotech

Despite COVID testing crash and stagnant base business, BD brightens 2023 outlook

Amid the standard roll call of earnings sheets released in recent weeks, nearly every diagnostics developer marked present has reported a severe drop-off in COVID-19 test sales for the fourth quarter ...
FierceBiotech

COVID testing crash sends BD's full-year revenues down even as base business soars

In the wake of a 2021 that saw BD chart a whopping 18% increase in its year-over-year revenue, the medtech giant was unable to recreate that success. For its fiscal year 2022, which ended Sept. 30, BD ...
Morningstar

BD Continues Growing Even as COVID-19 Testing Pulls Back

We are maintaining our $306 fair value estimate for narrow-moat Becton, Dickinson as we update our model following fiscal third-quarter results and updated full-year guidance. BD increased its revenue ...
Seeking Alpha

BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test

New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)), a leading global ...
Nasdaq

BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test

FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug ...